Table 4.
Standardised incidence ratios (SIR) for developing a second malignancy after first primary uveal melanoma according to latency; SIR (95% CIs)
| Characteristics | <5 years | 5–10 years | >10 years | Total* | ||||
| Obs. | SIR (95% CI) | Obs. | SIR (95% CI) | Obs. | SIR (95% CI) | Obs. | SIR (95% CI) | |
| Overall | 258 | 1.20† (1.06 to 1.35) | 181 | 1.09 (0.94 to 1.27) | 287 | 1.01 (0.90 to 1.14) | 726 | 1.09† (1.02 to 1.18) |
| Sex | ||||||||
| Male | 153 | 1.19† (1.01 to 1.39) | 116 | 1.15 (0.95 to 1.38) | 169 | 0.97 (0.83 to 1.13) | 438 | 1.09 (0.99 to 1.19) |
| Female | 105 | 1.21 (0.99 to 1.47) | 65 | 1.00 (0.77 to 1.28) | 118 | 1.08 (0.90 to 1.30) | 288 | 1.11 (0.98 to 1.24) |
| Race | ||||||||
| White | 256 | 1.21† (1.06 to 1.36) | 180 | 1.11 (0.95 to 1.28) | 283 | 1.02 (0.90 to 1.14) | 719 | 1.10† (1.02 to 1.18) |
| Black | 1 | 0.78 (0.02 to 4.32) | 1 | 1.08 (0.03 to 6.04) | 4 | 1.55 (0.42 to 3.97) | 6 | 1.25 (0.46 to 2.73) |
| Other races | 1 | 1.23 (0.03 to 6.87) | 0 | 0 | 0 | 0 | 1 | 0.57 (0.01 to 3.19) |
| Age at diagnosis of uveal melanoma | ||||||||
| <50 years | 15 | 1.36 (0.76 to 2.24) | 20 | 1.41 (0.86 to 2.17) | 69 | 0.97 (0.75 to 1.23) | 104 | 1.08 (0.88 to 1.31) |
| 50–70 years | 133 | 1.24† (1.04 to 1.47) | 113 | 1.15 (0.94 to 1.38) | 182 | 1.01 (0.87 to 1.17) | 428 | 1.11† (1.01 to 1.22) |
| >70 years | 110 | 1.13 (0.93 to 1.37) | 48 | 0.91 (0.67 to 1.21) | 36 | 1.10 (0.77 to 1.52) | 194 | 1.06 (0.92 to 1.22) |
| Primary site of uveal melanoma‡ | ||||||||
| Choroid | 217 | 1.20† (1.04 to 1.37) | 140 | 1.03 (0.9 to 1.2) | 220 | 1.01 (0.88 to 1.15) | 577 | 1.08 (0.99 to 1.17) |
| Ciliary body | 41 | 1.21 (0.87 to 1.64) | 41 | 1.42† (1.02 to 1.93) | 67 | 1.03 (0.80 to 1.31) | 149 | 1.17 (0.99 to 1.37) |
| Site of the next malignsancy§ | ||||||||
| Breast | 21 | 0.83 (0.51 to 1.27) | 17 | 0.91 (0.53 to 1.46) | 29 | 0.97 (0.65 to 1.39) | 67 | 0.91 (0.70 to 1.15) |
| Prostate | 45 | 1.20 (0.87 to 1.60) | 28 | 0.93 (0.62 to 1.35) | 47 | 0.91 (0.67 to 1.21) | 120 | 1.01 (0.83 to 1.20) |
| Colon and rectum | 26 | 1.02 (0.66 to 1.49) | 15 | 0.77 (0.43 to 1.27) | 28 | 0.86 (0.57 to 1.25) | 69 | 0.89 (0.69 to 1.13) |
| Lung and bronchus | 23 | 0.71 (0.45 to 1.06) | 31 | 1.25 (0.85 to 1.77) | 44 | 1.04 (0.75 to 1.39) | 98 | 0.98 (0.80 to 1.20) |
| Urinary bladder | 11 | 0.90 (0.45 to 1.61) | 11 | 1.13 (0.57 to 2.03) | 19 | 1.05 (0.63 to 1.64) | 41 | 1.03 (0.74 to 1.39) |
| Melanoma of the skin | 30 | 3.76† (2.54 to 5.37) | 12 | 1.92 (0.99 to 3.36) | 23 | 1.96† (1.24 to 2.94) | 65 | 2.51† (1.93 to 3.19) |
| Corpus uteri | 3 | 0.52 (0.11 to 1.53) | 6 | 1.48 (0.54 to 3.23) | 10 | 1.66 (0.80 to 3.05) | 19 | 1.20 (0.72 to 1.88) |
| Non-Hodgkin's lymphoma | 12 | 1.42 (0.73 to 2.48) | 4 | 0.60 (0.17 to 1.55) | 9 | 0.74 (0.34 to 1.40) | 25 | 0.92 (0.60 to 1.35) |
| Oral cavity and pharynx | 6 | 1.08 (0.40 to 2.36) | 4 | 0.99 (0.27 to 2.53) | 3 | 0.47 (0.10 to 1.37) | 13 | 0.81 (0.43 to 1.39) |
| Thyroid | 7 | 3.16† (1.27 to 6.51) | 1 | 0.62 (0.02 to 3.47) | 3 | 1.16 (0.24 to 3.40) | 11 | 1.72 (0.86 to 3.07) |
| Ovary | 3 | 1.03 (0.21 to 3.00) | 1 | 0.47 (0.01 to 2.63) | 6 | 1.80 (0.66 to 3.91) | 10 | 1.19 (0.57 to 2.19) |
| Leukaemia | 5 | 0.82 (0.27 to 1.90) | 7 | 1.46 (0.59 to 3.01) | 11 | 1.25 (0.53 to 2.24) | 23 | 1.17 (0.74 to 1.75) |
| Kidney and renal pelvis | 15 | 2.62† (1.47 to 4.32) | 5 | 1.13 (0.37 to 2.63) | 11 | 1.41 (0.70 to 2.51) | 31 | 1.72† (1.17 to 2.45) |
| Eye and orbit | 3 | 8.01† (1.65 to 23.41) | 2 | 7.25 (0.88 to 26.20) | 5 | 10.84† (3.52 to 25.30) | 10 | 9.00† (4.31 to 16.55) |
Bold values are statistically significant (p<.001)
*Single patient may have multiple tumours. Further details are available in (online supplemental table 9).
†Significant with p<0.05.
‡Using primary site variable.
§Using ICD-O-3 site recode.
ICD, International Classification of Diseases; Obs., observed.